[Skip to Content]
[Skip to Content Landing]
Views 200
Citations 0
Comment & Response
March 2015

Treatment of Borderline Elevated Thyrotropin Levels

Author Affiliations
  • 1Manchester Medical Association, Manchester, England
JAMA Intern Med. 2015;175(3):466. doi:10.1001/jamainternmed.2014.7847

To the Editor Over and above the substantial risk of developing a suppressed thyrotropin level following replacement therapy,1 there is a risk that thyroid replacement therapy may precipitate transition to persistent atrial fibrillation (AF), with all its attendant sequelae, when replacement therapy is administered to patients with unrecognized paroxysmal AF (PAF).